These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

55 related articles for article (PubMed ID: 12496875)

  • 1. A comparison of three free and total PSA assays.
    Roth HJ; Stewart SC; Brawer MK
    Prostate Cancer Prostatic Dis; 1998 Dec; 1(6):326-331. PubMed ID: 12496875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 3 investigational assays for the free form of prostate specific antigen.
    Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
    J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The variation of percent free prostate-specific antigen determined by two different assays.
    Yang CR; Ou YC; Horng YY; Lee HS
    Anticancer Res; 2003; 23(1B):707-11. PubMed ID: 12680171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen.
    Sotelo RJ; Mora KE; Pérez LH; Novoa J; Carmona O; De Andrade R; Borges RE; Parada D; Loeb S; Catalona WJ
    Urology; 2007 Jun; 69(6):1143-6. PubMed ID: 17572203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analytical comparison of the three most commonly used prostate-specific antigen assays: Tandem-R, Tandem-E, and IMx.
    Oesterling JE; Moyad MA; Wright GL; Beck GR
    Urology; 1995 Oct; 46(4):524-32. PubMed ID: 7571222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated Cobas Core PSA assays: sensitive, precise, and specific measurement of PSA-total and PSA-total/PSA-free ratio.
    Groche D; Trebo R; Peters I; Pfleiderer P
    Anticancer Res; 1999; 19(4A):2767-70. PubMed ID: 10470238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complexed prostate specific antigen (PSA) reduces unnecessary prostate biopsies in the 2.6-4.0 ng/mL range of total PSA.
    Parsons JK; Brawer MK; Cheli CD; Partin AW; Djavan R
    BJU Int; 2004 Jul; 94(1):47-50. PubMed ID: 15217429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
    Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
    J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer.
    Partin AW; Brawer MK; Subong EN; Kelley CA; Cox JL; Bruzek DJ; Pannek J; Meyer GE; Chan DW
    Prostate Cancer Prostatic Dis; 1998 Jun; 1(4):197-203. PubMed ID: 12496895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate-specific antigen (PSA) complexed to alpha1-antichymotrypsin improves prostate cancer detection using total PSA in Japanese patients with total PSA levels of 2.0-4.0 ng/mL.
    Kobayashi T; Kamoto T; Nishizawa K; Mitsumori K; Ogura K; Ide Y
    BJU Int; 2005 Apr; 95(6):761-5. PubMed ID: 15794778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics.
    Stephan C; Cammann H; Meyer HA; Müller C; Deger S; Lein M; Jung K
    BJU Int; 2008 Sep; 102(7):799-805. PubMed ID: 18522632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.